282 results on '"Alvarez-Larran A"'
Search Results
2. P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY
3. P1054: CLINICAL CHARACTERISTICS AND OUTCOMES IN 175 PATIENTS WITH MYELOFIBROSIS ACCORDING TO GENOMIC CLASSIFICATION USING NEXT-GENERATION SEQUENCING
4. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
5. Breakthrough infections in MPN-COVID vaccinated patients
6. Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
7. Second versus first wave of COVID-19 in patients with MPN
8. Breakthrough infections in MPN-COVID vaccinated patients
9. Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
10. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
11. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
12. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet
13. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
14. Correction to: Low‑risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
15. Long-term follow-up of recovered MPN patients with COVID-19
16. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
17. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model
18. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
19. DNMT3A/TET2/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: an observational study
20. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
21. P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19
22. Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study
23. PB0954 Endothelial Dysfunction in Myeloproliferative Neoplasms Debuting with Splanchnic Vein Thrombosis
24. Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study
25. P1054: CLINICAL CHARACTERISTICS AND OUTCOMES IN 175 PATIENTS WITH MYELOFIBROSIS ACCORDING TO GENOMIC CLASSIFICATION USING NEXT-GENERATION SEQUENCING
26. P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY
27. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
28. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study
29. Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors
30. Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
31. Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study
32. Coexisting Myeloproliferative and Lymphoproliferative Neoplasms: A European Multicenter Retrospective Study
33. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms
34. BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia
35. Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia
36. Discrimination between tumour epithelium and stroma via perception-based features
37. Essential thrombocythemia: Baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients
38. Dual Inhibition of NF-Kb and JAK/STAT Pathways Reverts Myelofibrosis-like Phenotype in an In Vivo Murine Model
39. Coexisting Myeloproliferative and Lymphoproliferative Neoplasms: A European Multicenter Retrospective Study
40. Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study
41. Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
42. Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors
43. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
44. Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19
45. Determinants of early triage for hospitalization in myeloproliferative neoplasm ( MPN) patients with COVID ‐19
46. MPN-135 Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
47. Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
48. Dual Inhibition of NF-Kb and JAK/STAT Pathways Reverts Myelofibrosis-like Phenotype in an In Vivo Murine Model
49. P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19
50. Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.